BTMD

Biote Corp. (BTMD)
Healthcare • Medical Care Facilities • $1.54 • MCap: 52,374,324 🌐
https://www.biote.com • biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and meet other administrative requirements; inventory management software to facilitate ordering and inventory control; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female patients. The company was founded in 2012 and is headquartered in Irving, Texas.
Buy Decision Core
Total Score
50
Business Quality
12
Financial Strength
6
Growth Outlook
5
Momentum
2
Price Action
Current
1.54
52W High
3.46
52W Low
1.30
Above 50DMA
1.92 (-19.43%)
Above 200DMA
2.10 (-26.38%)
Relative Strength
Relative Strength
-0.36
RS 3M
-0.34
RS 6M
-0.18
RS 9M
-0.4
RS 12M
-0.53
Fundamentals
Revenue Growth
-0.10%
Earnings Growth
0%
ROE
0%
ROA
0.14%
Valuation
PE (Fwd)
3.43
PEG
0
P/B
-0.65
Upside
69.06%
Risk
Beta
1.61
Short %
0.03
Risk Score
9.00
Analyst
Rating
none
Target
2.61
Beta
1.61
Analysts
0


Total Score
50
Upside
69.06%
Relative Strength
-0.36
Beta
1.61
Why Buy?
  • PEG Ratio below 1 (attractive valuation)
  • Trading below book value
  • Analyst upside exceeds 15%
Key Risks
  • Revenue growth is negative
  • High volatility (Beta > 1.5)
  • Weak long-term relative strength
Score Breakdown
Business
12
Financial
6
Growth
5
Valuation
15
Risk
3
Momentum
2
Technical
52W High: 3.46
52W Low: 1.30
Above 50DMA: -19.43%
Above 200DMA: -26.38%
Valuation
Forward PE: 3.43
PEG: 0
P/B: -0.65
Upside: 69.06%
Risk
Beta: 1.61
Short Float: 0.03%
ROE: 0%
ROA: 0.14%